Condition
Cutaneous T-Cell Lymphoma Refractory
Total Trials
4
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Recruiting1
Active Not Recruiting1
Unknown1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07535710Phase 1Not Yet RecruitingPrimary
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
NCT06810778Phase 1Recruiting
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
NCT04745234Phase 2Active Not Recruiting
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
NCT04712864Phase 1Unknown
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
Showing all 4 trials